心血管危险因素数量增加对真性红细胞增多症血栓形成和生存无影响。 - Suppr

Suppr

超能文献

No Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera.

作者信息

Krečak Ivan, Morić Perić Martina, Zekanović Ivan, Holik Hrvoje, Coha Božena, Gverić-Krečak Velka, Lucijanić Marko

机构信息

Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia,

Department of Internal Medicine, General Hospital of Zadar, Zadar, Croatia.

出版信息

Oncol Res Treat. 2021;44(4):201-203. doi: 10.1159/000514347. Epub 2021 Jan 27.

DOI:10.1159/000514347

PMID:33503631

Abstract

摘要

相似文献

No Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera.心血管危险因素数量增加对真性红细胞增多症血栓形成和生存无影响。

Oncol Res Treat. 2021;44(4):201-203. doi: 10.1159/000514347. Epub 2021 Jan 27.

Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?原发性骨髓纤维化患者的心血管风险：血栓形成风险与生存：伴有心血管危险因素的低危原发性骨髓纤维化患者应用细胞减灭治疗是否有益？

Oncol Res Treat. 2020;43(10):526-530. doi: 10.1159/000509376. Epub 2020 Aug 7.

Efficacy and safety of low-dose aspirin in polycythemia vera.低剂量阿司匹林治疗真性红细胞增多症的疗效与安全性

N Engl J Med. 2004 Jan 8;350(2):114-24. doi: 10.1056/NEJMoa035572.

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.一大群真性红细胞增多症患者的血管和肿瘤风险

J Clin Oncol. 2005 Apr 1;23(10):2224-32. doi: 10.1200/JCO.2005.07.062. Epub 2005 Feb 14.

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.放血疗法方案强度与真性红细胞增多症血栓形成风险无相关性：来自真性红细胞增多症低剂量阿司匹林欧洲协作组及真性红细胞增多症细胞减灭治疗临床试验的证据。

Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2.

Risk factors for thrombosis in polycythemia vera.真性红细胞增多症中血栓形成的危险因素。

Br J Haematol. 1988 Jul;69(3):422-3. doi: 10.1111/j.1365-2141.1988.tb02387.x.

Massive intraventricular thrombus in polycythemia vera.真性红细胞增多症中的巨大脑室内血栓形成。

J Card Surg. 2009 Mar-Apr;24(2):110-2. doi: 10.1111/j.1540-8191.2008.00621.x.

Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis.真性红细胞增多症——一例病例报告及血栓形成增加的致病机制探讨

Angiology. 2002 Sep-Oct;53(5):587-91. doi: 10.1177/000331970205300514.

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.真性红细胞增多症：1213例患者20年随访的自然病史。意大利真性红细胞增多症研究组

Ann Intern Med. 1995 Nov 1;123(9):656-64. doi: 10.7326/0003-4819-123-9-199511010-00003.

Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.慢性肾脏病可能是原发性血小板增多症和真性红细胞增多症患者发生血栓的一个危险因素。

Int J Hematol. 2020 Sep;112(3):377-384. doi: 10.1007/s12185-020-02898-7. Epub 2020 Jun 8.

引用本文的文献

No impact of steatotic liver disease on clinical outcomes in patients with essential thrombocythemia and polycythemia vera: A pilot study.脂肪性肝病对原发性血小板增多症和真性红细胞增多症患者临床结局无影响：一项初步研究。

Heliyon. 2024 Jun 11;10(12):e32827. doi: 10.1016/j.heliyon.2024.e32827. eCollection 2024 Jun 30.

Diabetes mellitus, metformin, and the risk of MPN.糖尿病、二甲双胍与骨髓增殖性肿瘤风险

Blood Adv. 2024 Nov 26;8(22):5929-5931. doi: 10.1182/bloodadvances.2024013772.

Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.真性红细胞增多症患者心血管风险的诊断和管理。

Vasc Health Risk Manag. 2023 Nov 22;19:765-778. doi: 10.2147/VHRM.S429995. eCollection 2023.

Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.BCR::ABL1 阴性慢性骨髓增殖性肿瘤患者心血管风险因素管理的优化：现有知识和观点。

Ann Hematol. 2024 May;103(5):1513-1523. doi: 10.1007/s00277-023-05426-9. Epub 2023 Sep 4.

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms.慢性骨髓增殖性肿瘤患者的多重用药、潜在不适当用药及药物相互作用

Biomedicines. 2023 Apr 27;11(5):1301. doi: 10.3390/biomedicines11051301.

Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.原发性骨髓纤维化和特发性血小板增多症的危险分层和治疗进展。

Curr Hematol Malig Rep. 2022 Oct;17(5):155-169. doi: 10.1007/s11899-022-00670-8. Epub 2022 Aug 6.

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.中性粒细胞与淋巴细胞比值是真性红细胞增多症静脉血栓形成的新预测因子。

Blood Cancer J. 2022 Feb 10;12(2):28. doi: 10.1038/s41408-022-00625-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验